Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$145.9M
99M shares
52-week range
$0.68 – $2.22
49% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
2.82%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $294.0K | $1.5M | $6.8M | $11.0M | $12.9M | $13.6M |
| Cost of revenue | $0 | $771.0K | $2.7M | $5.9M | $6.3M | $7.0M | $6.8M |
| Gross profit | $0 | −$477.0K | −$1.2M | $907.0K | $4.8M | $5.9M | $6.8M |
| Gross margin | — | -162.2% | -78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| R&D | $13.4M | $14.6M | $25.8M | $28.2M | $22.5M | $22.5M | $17.5M |
| Operating income | −$20.0M | −$23.5M | −$64.9M | −$73.9M | −$48.1M | −$43.2M | −$37.1M |
| EBITDA | −$19.8M | −$23.2M | −$64.1M | −$72.1M | −$43.2M | −$39.7M | −$33.4M |
| Net income | −$18.8M | −$23.4M | −$64.8M | −$73.2M | −$44.2M | −$40.7M | −$35.6M |
| Net margin | — | -7944.6% | -4333.8% | -1073.7% | -401.0% | -315.9% | -262.3% |
| EPS (diluted) | -4.06 | -0.93 | -0.92 | -1.04 | -0.62 | -0.56 | -0.43 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $20M | $-0.35 | $-0.35–$-0.34 | 2 |
| 2027 | $26M | $-0.34 | $-0.34–$-0.33 | 1 |
| 2028 | $35M | $-0.31 | $-0.31–$-0.31 | 1 |
| 2029 | $29M | $-0.29 | $-0.29–$-0.29 | 1 |
Forward consensus · source: Financial Modeling Prep
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
www.hyperfine.ioNo one on the platform currently holds HYPR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 730,233 | $788.7K |
| Execution date | Ratio |
|---|---|
| 2003-08-13 | 1-for-10reverse |
No one on the platform has traded HYPR yet.
| $68M |
| — |
| LUNGPulmonx Corporation | $1.33 | +6.40% | $56M | — |
| NSPRInspireMD, Inc. | $0.68 | -5.60% | $32M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$HYPR no interest rate hikes this year more than likely
View on StockTwits ↗$HYPR a colleague told me about this penny stock . They had a exhibit at one of my sister HCA hospital . Can anyone sell it to me ? Why should I buy ?
View on StockTwits ↗$HYPR Just look at BFLY! Why can’t HYPR get some of that love and devotion?
View on StockTwits ↗$HYPR congrats to $HYPR for it’s inclusion into the Russell 2000
View on StockTwits ↗$HYPR it’s funny how the quiet ones can become the strongest.
View on StockTwits ↗$HYPD I deciphered the daily $HYPR stock price change relative to the $HYPE.X token. Here you have the accurate formula: %change in $HYPD = -abs(%change in $HYPE.X ). Infallible.
View on StockTwits ↗$HYPR https://x.com/hyperfine/status/2069845915595153718?s=61
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 8.8× sales vs its 10.6× historical median P/S.
Fair value ≈ $1.73 · price $1.44 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.